Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02311946 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02311946 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 60 participants.
The verdict
NCT02311946, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will investigate whether concurrent administration of rabeprazole, an antacid known as a proton pump inhibitor, alters the absorption of the drug palbociclib when given as one of six experimental formulations.
Interventions
- DRUG Palbociclib + Rabeprazole
- DRUG Palbociclib Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02311946
The ClinicalTrials.gov registry entry for NCT02311946 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib + Rabeprazole is the first listed.
NCT02311946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02311946 about?
NCT02311946 is a clinical study titled "A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib". This study will investigate whether concurrent administration of rabeprazole, an antacid known as a proton pump inhibitor, alters the absorption of the drug palbociclib when given as one of six experimental formulations.
What is the current status of trial NCT02311946?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-01. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02311946?
The interventions under investigation include: Palbociclib + Rabeprazole (DRUG), Palbociclib Alone (DRUG).
Who is sponsoring clinical trial NCT02311946?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.